Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M

Zai Lab Ltd

2025-FY EPS reported -$0.16 revenue$460,156,000

Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
Net loss Q4 $50.4M (loss per ADS $0.46) vs $81.7M loss Q4 2024; FY loss $175.5M vs $257.1M.
Cash $789.6M as of Dec 31, 2025; R&D expenses $61.6M Q4 (+18% YoY).
KarXT approved in China Dec 2025; commercial launch H1 2026; NRDL renewals for VYVGART, NUZYRA, ZEJULA.
Global pipeline: zoci (DLL3 ADC) advancing to three registration-enabling studies; ZL-1503 Phase 1 data H2 2026; ZL-1311 IND by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.